Establishing a clinic-based pancreatic cancer and periampullary tumour research registry in Quebec

Current Oncology

Volumn 22, Issue 2, 2015, Pages 113-121

  Smith, A L ^a,b   Bascunana C ^a,b   Hall, A ^a,b   Salman, A ^a,c   Andrei, A Z ^a,b   Volenik, A ^a,b,d   Rothenmund, H ^a,b,d   Ferland, D ^a,c   Lamoussenery, D ^c   Kamath, A S ^c   Amre, R ^c   Caglar, D ^c   Gao, Z H ^c   Haegert, D G ^c   Kanber, Y ^c   Michel, R P ^c   Omeroglu Altinel G ^c   Asselah, J ^c   Bouganim, N ^c   Kavan, P ^c   Arena, G ^c   Barkun, J ^c   Chaudhury, P ^c   Gallinger, S ^e   Foulkes, W D ^a,d   Omeroglu, A ^c   Metrakos, P ^a,c   Zogopoulos, George ^a,b,c,d   more..

^a RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b MCGILL UNIVERSITY   (Canada)

^c MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^d MCGILL UNIVERSITY   (Canada)

^e NONE

Author keywords

Cancer genetics; Pancreatic cancer; Periampullary tumours; Research registry; Translational research

Indexed keywords

ADULT; ARTICLE; BLOOD SAMPLING; CANADA; CANCER REGISTRY; CANCER RESEARCH; DNA EXTRACTION; FAMILY HISTORY; FEMALE; GENETIC COUNSELING; GENETIC PREDISPOSITION; HISTOPATHOLOGY; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS BIOPSY; PANCREAS CANCER; PEDIGREE ANALYSIS; QUESTIONNAIRE; RISK ASSESSMENT; SALIVA ANALYSIS;

EID: 84928236720     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.22.2300     Document Type: Article

References (46)

1. Canadian Cancer Society’s Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2014. Toronto, ON: Canadian Cancer Society; 2014.
2. Howlader N, Noone AM, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975–2011 [Web resource]. Bethesda, MD: U.S. National Cancer Institute; 2013. [Downloadable from: http://seer.cancer.gov/csr/1975_2011; cited November 26, 2014]
3. Hurton S, MacDonald F, Porter G, Walsh M, Molinari M. The current state of pancreatic cancer in Canada: incidence, mortality, and surgical therapy. Pancreas 2014;43:879–85.
4. Hidalgo M. Pancreatic cancer. N Eng J Med 2010;362:1605–17. [Erratum in: N Engl J Med 2010;363:298]
5. Wolfgang CL, Herman JM, Laheru DA, et al. Recent progress in pancreatic cancer. CA Cancer J Clin 2013;63:318–48.
6. Klein AP. Identifying people at a high risk of developing pancreatic cancer. Nat Rev Cancer 2013;13:66–74.
7. Borgida AE, Ashamalla S, Al-Sukhni W, et al. Management of pancreatic adenocarcinoma in Ontario, Canada: a population-based study using novel case ascertainment. Can J Surg 2011;54:54–60.
8. Scriver CR. Human genetics: lessons from Quebec populations. Annu Rev Genom Human Genet 2001;2:69–101.
9. Kermanshahi TR, Jayachandran P, Chang DT, Pai R. Lef-1 is frequently expressed in colorectal carcinoma and not in other gastrointestinal tract adenocarcinomas: an immunohistochemical survey of 602 gastrointestinal tract neoplasms. Appl Immunohistochem Mol Morphol 2014;22:728–34.
10. Keane MG, Horsfall L, Rait G, Pereira SP. A case–control study comparing the incidence of early symptoms in pancreatic and biliary tract cancer. BMJ Open 2014;4:e005720.
11. Simard J, Dumont M, Moisan AM, et al. Evaluation of BRCA1 and BRCA2 mutation prevalence, risk prediction models and a multistep testing approach in French-Canadian families with high risk of breast and ovarian cancer. J Med Genet 2007;44:107–21.
12. Ghadirian P, Robidoux A, Zhang P, et al. The contribution of founder mutations to early-onset breast cancer in French- Canadian women. Clin Genet 2009;76:421–6.
13. Cavallone L, Arcand SL, Maugard CM, et al. Comprehensive BRCA1 and BRCA2 mutation analyses and review of French Canadian families with at least three cases of breast cancer. Fam Cancer 2010;9:507–17.
14. Ferrone CR, Levine DA, Tang LH, et al. BRCA germline mutations in Jewish patients with pancreatic adenocarcinoma. J Clin Oncol 2009;27:433–8.
15. Armaou S, Pertesi M, Fostira F, et al. Contribution of BRCA1 germ-line mutations to breast cancer in Greece: a hospitalbased study of 987 unselected breast cancer cases. Br J Cancer 2009;101:32–7.
16. Janavičius R. Founder BRCA1/2 mutations in the Europe: implications for hereditary breast–ovarian cancer prevention and control. EPMA J 2010;1:397–412.
17. Meindl A, On behalf of the German Consortium for Hereditary Breast and Ovarian Cancer. Comprehensive analysis of 989 patients with breast or ovarian cancer provides BRCA1 and BRCA2 mutation profiles and frequencies for the German population. Int J Cancer 2002;97:472–80.
18. Brozek I, Cybulska C, Ratajska M, et al. Prevalence of the most frequent BRCA1 mutations in Polish population. J Appl Genet 2011;52:325–30.
19. Tikhomirova L, Sinicka O, Smite D, Eglitis J, Hodgson SV, Stengrevics A. High prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia. Fam Cancer 2005;4:77–84.
20. Wang W, Chen S, Brune KA, Hruban RH, Parmigiani G, Klein AP. Pancpro: risk assessment for individuals with a family history of pancreatic cancer. J Clin Oncol 2007;25:1417–22.
21. Nkondjock A, Krewski D, Johnson KC, Ghadirian P On behalf of the Canadian Cancer Registries Epidemiology Research Group. Specific fatty acid intake and the risk of pancreatic cancer in Canada. Br J Cancer 2005;92:971–7.
22. McWilliams RR, Rabe KG, Olswold C, de Andrade M, Petersen GM. Risk of malignancy in first-degree relatives of patients with pancreatic carcinoma. Cancer 2005;104:388–94.
23. Hurton S, Macdonald F, Porter G, Walsh M, Molinari M. The current state of pancreatic cancer in Canada: incidence, mortality, and surgical therapy. Pancreas 2014;43:879–85.
24. Olson SH, Kurtz RC. Epidemiology of pancreatic cancer and the role of family history. J Surg Oncol 2013;107:1–7.
25. Cheung MC, Yang R, Byrne MM, Solorzano CC, Nakeeb A, Koniaris LG. Are patients of low socioeconomic status receiving suboptimal management for pancreatic adenocarcinoma? Cancer 2010;116:723–33.
26. Lucenteforte E, La Vecchia C, Silverman D, et al. Alcohol consumption and pancreatic cancer: a pooled analysis in the International Pancreatic Cancer Case–Control Consortium (PanC4). Ann Oncol 2012;23:374–82.
27. Huxley R, Ansary-Moghaddam A, Berrington de González A, Barzi F, Woodward M. Type-ii diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 2005;92:2076–83.
28. Chari ST, Leibson CL, Rabe KG, Ransom J, de Andrade M, Petersen GM. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology 2005;129:504–11.
29. Duell EJ, Lucenteforte E, Olson SH, et al. Pancreatitis and pancreatic cancer risk: a pooled analysis in the International Pancreatic Cancer Case–Control Consortium (PanC4). Ann Oncol 2012;23:2964–70.
30. Masamune A. Genetics of pancreatitis: the 2014 update. Tohoku J Exp Med 2014;232:69–77.
31. Arslan AA, Helzlsouer KJ, Kooperberg C, et al. On behalf of the Pancreatic Cancer Cohort Consortium (PanScan). Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). Arch Intern Med 2010;170:791–802.
32. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009;324:217.
33. Roberts NJ, Jiao Y, Yu J, et al. ATM mutations in patients with hereditary pancreatic cancer. Cancer Discov 2012;2:41–6.
34. Becker AE, Hernandez YG, Frucht H, Lucas AL. Pancreaticductal adenocarcinoma: risk factors, screening, and early detection. World J Gastroenterol 2014;20:11182–98.
35. Petersen GM, de Andrade M, Goggins M, et al. Pancreatic cancer genetic epidemiology consortium. Cancer Epidemiol Biomarkers Prev 2006;15:704–10.
36. Knudson AG. Two genetic hits (more or less) to cancer. Nat Rev Cancer 2001;1:157–62.
37. Abbott A. Manhattan versus Reykjavik. Nature 2000;406:340–2.
38. Neuhausen SL. Founder populations and their uses for breast cancer genetics. Breast Cancer Res 2000;2:77–81.
39. Sokolenko AP, Iyevleva AG, Preobrazhenskaya EV, et al. High prevalence and breast cancer predisposing role of the BLM c.1642 C>T (Q548X) mutation in Russia. Int J Cancer 2012;130:2867–73.
40. Ghadirian P, Boyle P, Simard A, Baillargeon J, Maisonneuve P, Perret C. Reported family aggregation of pancreatic cancer within a population-based case–control study in the Francophone community in Montreal, Canada. Int J Pancreatol 1991;10:183–96.
41. Farmer H, McCabe N, Lord CJ, et al. Targeting the dna repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917–21.
42. Fong PC, Boss DS, Yap TA, et al. Inhibition of poly(adp-ribose) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009;361:123–34.
43. Lowery MA, Kelsen DP, Stadler ZK, et al. An emerging entity: pancreatic adenocarcinoma associated with a known BRCA mutation: clinical descriptors, treatment implications, and future directions. Oncologist 2011;16:1397–402.
44. Imyanitov EN, Moiseyenko VM. Drug therapy for hereditary cancers. Hered Cancer Clin Pract 2011;9:5.
45. Zogopoulos G, Al-Sukhni A, Moore S, et al. Platinum-based chemotherapy in patients with pancreatic cancer and germline BRCA2 mutations [abstract]. HPB (Oxford) 2011;13(suppl 1):77.
46. Tran B, Moore S, Zogopoulos G, et al. Platinum-based chemotherapy in pancreatic adenocarcinoma (pc) associated with BRCA mutations: a translational case series [abstract 217]. J Clin Oncol 2012;30:. [Available online at: http://meetinglibrary.asco.org/ content/87854-115; cited February 12, 2015]